Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Air pollution effects Cystic Fibrosis Sufferers

University of Washington (UW) researchers have shown for the first time that air pollution has adverse effects on people with cystic fibrosis (CF). The research results are published in the April 1 edition of the American Journal of Respiratory and Critical Care Medicine.

29 Mar 2004

Almost half of all medicines globally are used irrationally according to WHO

Almost half of all medicines globally are used irrationally. This, say medicines experts at the World Health Organization (WHO), can have severe consequences: adverse drug reactions, drug resistance, protracted illness and even death. In addition, the financial cost incurred by individuals and governments due to irrational use is unnecessary and often extremely high, particularly in developing countries where patients often pay for medicines out of pocket.

29 Mar 2004

A common antibiotic used to treat arthritis and acne shows promise for limiting the severity of spinal cord and brain injuries

When a fall, car crash, bullet, or knife crushes or cuts a spinal cord, the injury does not stop there. Rather, tissues continue to discharge toxic chemicals for hours, even days and weeks. These chemicals kill and disable nerve cells some distance away from the core injury, compounding the damage and making rehabilitation more difficult or impossible.

26 Mar 2004

Scientists discover a method to detect trace levels of swine antibiotics in the groundwater.

Scientists from the Department of Soil, Water, & Climate at University of Minnesota have developed a simple method to quantify two types of antibiotics in animal manures, and surface and ground waters. Chlortetracycline and tylosin antibiotics are commonly used for growth promotion in swine production.

25 Mar 2004

British company to launch "super bug tester" into UK hospitals

MRSA is the first test to be developed from Acolyte’s BacLite® testing platform. BacLite reduces the time for identifying both the type of bacteria and, more importantly, the antibiotic sensitivity of the bacteria from the current 3-4 day standard to just 2-5 hours. This time advantage will mean clinicians will be able to treat, much more effectively, serious bacterial infections and prevent potentially fatal complications, such as sepsis and septic shock, from developing.

24 Mar 2004

Carbon Dioxide may be used in medical implants

Carbon dioxide, an environmentally friendly solvent for dyeing and dry cleaning, may become a valuable new tool for making medical implants, according to a study at Ohio State University.

23 Mar 2004

EU gives 32 million Euro for vaccines to stop tuberculosis

The European Commission today launched the largest-ever collaborative tuberculosis (TB) initiative for World TB-day, March 24. Fifty-two research teams from academia and industry from 15 European and African countries are joining forces with the European Commission to help eradicate TB. Globally, TB kills 2 million people a year, with one-third of the world's population currently infected with the bacillus, Mycobacterium tuberculosis (Mtb). While most cases and deaths occur in developing countries, resistant Mtb strains are mainly found among the poorest people in developed countries, as incomplete treatment increases drug resistance. The European Union is confronting the re-emerging threat of TB by investing €32 million in two overlapping research projects. This cash will be used in an accelerated effort to develop new, effective vaccines to fight TB.

23 Mar 2004

DNA repair enzymes to fight cancer

The body has a set of DNA repair enzymes that clean up damage to the genome, to reduce potential problems. Many commonly used cancer chemotherapies work by alkylating DNA. However, the DNA repair enzymes are just as capable of repairing this alkylation as if it were damage from any other source, and so they act to overcome the effects of the therapy, reducing its effectiveness.

22 Mar 2004

New drug to treat urinary tract infections, a step closer

Depomed, Inc. today announced top line results from the Phase III clinical trial of its Ciprofloxacin GR, an extended release formulation of ciprofloxacin HCl, which is used to treat urinary tract infections. The data confirmed Phase II results, demonstrating that Depomed's once-daily Ciprofloxacin GR eliminated the organisms responsible for urinary tract infections as effectively as twice-daily CIPRO(R), but with fewer gastrointestinal side effects, specifically fewer incidences of nausea and diarrhea.

22 Mar 2004

Bacteria Live in the Esophagus!

The esophagus isn't merely a tube for food traveling from the mouth to the stomach, it also provides an environment for bacteria to live, according to a new study by NYU School of Medicine scientists that overturns the general belief that the esophagus is free of bacteria.

22 Mar 2004